Azzam Taktak

Azzam Taktak

Auto-generated profile, based on publicly available information

Azzam Taktak

Department of Medial Physics and Clinical Engineering, Liverpool University Hospitals NHS Foundation Trust, Liverpool, L7 8XP, UK

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2020 in Cancers
Verified
Journal Article
Open access
STSophie Thornton
Sophie Thornton
Sarah E. CouplandSarah E. Coupland
Sarah E. Coupland
LOLisa Olohan
Lisa Olohan
JSJulie Sibbring
Julie Sibbring
JKJohn Kenny
John Kenny
HKHelen Kalirai
Helen Kalirai
Uveal melanoma (UM) has well-characterised somatic copy number alterations (SCNA) in chromosomes 1, 3, 6 and 8, in addition to mutations in GNAQ, GNA11, CYSLTR2, PLCB4, BAP1, SF3B1 and EIF1AX, most being linked to metastatic-risk. To gain further insight into the molecular landscape of UM, we designed a targeted next-generation sequencing (NGS) panel to detect SCNA and mutations in routine clinical UM samples. We compared hybrid-capture and amplicon-based target enrichment methods and tested a larger cohort of primary UM samples on the best performing panel. UM clinical samples processed either as fresh-frozen, formalin-fixed paraffin embedded (FFPE), small intraocular biopsies or following irradiation were successfully profiled using NGS, with hybrid capture outperforming the PCR-based enrichment methodology. We identified monosomy 3 (M3)-UM that were wild-type for BAP1 but harbored SF3B1 mutations, novel frameshift deletions in SF3B1 and EIF1AX, as well as a PLCB4 mutation outside of the hotspot on exon 20 coinciding with a GNAQ mutation in some UM. We observed samples that harboured mutations in both BAP1 and SF3B1, and SF3B1 and EIF1AX, respectively. Novel mutations were also identified in TTC28, KTN1, CSMD1 and TP53BP1. NGS can simultaneously assess SCNA and mutation data in UM, in a reliable and reproducible way, irrespective of sample type or previous processing. BAP1 and SF3B1 mutations, in addition to 8q copy number, are of added importance when determining UM patient outcome.

1 April 2015 in Experimental Hematology & Oncology
Verified
Journal Article
Open access
PDF file
SMStephen Middle
Stephen Middle
Sarah E. CouplandSarah E. Coupland
Sarah E. Coupland
ATAzzam Taktak
Azzam Taktak
VKVictoria Kidgell
Victoria Kidgell
JSJoseph Slupsky
Joseph Slupsky
KTKathleen June Till
Kathleen June Till
The aim of this study was to elucidate the mechanisms responsible for the location of B-cell non-Hodgkin’s lymphoma (B-NHL) at different anatomical sites. We speculated that the malignant B cells in these disorders have the potential for trafficking between blood and secondary lymphoid organs (SLO) or extranodal sites and that their preferential accumulation at different locations is governed by the expression of key molecules that regulate the trafficking of normal lymphocytes. Biopsy or blood samples from 91 cases of B-NHL affecting SLO (n = 27), ocular adnexae (n = 51) or blood (n = 13) were analysed by immunohistochemistry or flow cytometry for the expression of the following molecules: CCR7, CCL21 and αL (required for the entry of normal lymphocytes into SLO); CXCR4, CXCL12 and α4 (required for entry into extranodal sites); CXCR5, CXCL13 and S1PR2 (required for tissue retention); S1PR1 and S1PR3 (required for egress into the blood). The expression of each of these molecules was then related to anatomical location and histological subtype. The expression of motility/adhesion molecules varied widely between individual patient samples and correlated much more strongly with anatomical location than with histological subtype. SLO lymphomas [comprising 10 follicular lymphoma (FL), 8 diffuse large B-cell lymphoma (DLBCL), 4 mantle-cell lymphoma (MCL) and 5 marginal-zone lymphoma (MZL)] were characterised by pronounced over-expression of S1PR2, suggesting that the malignant cells in these lymphomas are actively retained at the site of clonal expansion. In contrast, the malignant B cells in ocular adnexal lymphomas (10 FL, 9 DLBCL, 4 MCL and 28 MZL) expressed a profile of molecules suggesting a dynamic process of trafficking involving not only tissue retention but also egress via S1PR3 and homing back to extranodal sites via CXCR4/CXCL12 and α4. Finally, leukaemic lymphomas (6 FL, 5 MCL and 2 MZL) were characterised by aberrant expression of the egress receptor S1PR1 and low expression of molecules required for tissue entry/retention. In summary, our study strongly suggests that anatomical location in B-NHL is governed by the differential expression of specific adhesion/motility molecules. This novel observation has important implications for therapeutic strategies that aim to disrupt protective micro-environmental interactions.

1 August 2007 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
ATA. Taktak
A. Taktak
LAL. Antolini
L. Antolini
MAMin Aung
Min Aung
PBPatrizia Boracchi
Patrizia Boracchi
ICI. Campbell
I. Campbell
EBElia Biganzoli
Elia Biganzoli

1 March 2021 in Computers in Biology and Medicine
Verified
Journal Article
Open access
AEAntonio Eleuteri
Antonio Eleuteri
ARAlda Cunha Rola
Alda Cunha Rola
HKHelen Kalirai
Helen Kalirai
RHRumana Hussain
Rumana Hussain
JSJoseph Sacco
Joseph Sacco
ATAzzam F.G. Taktak
Azzam F.G. Taktak
This paper outlines a method for cost-utility analysis of liver screening for metastases in patients with posterior uveal melanoma (UM). A semiparametric model of the cumulative incidence of onset of liver metastases was fitted to a retrospective data set of 615 subjects with clinical follow-up with respect to liver surveillance imaging and outcome. The model was internally validated via bootstrap resampling in terms of its discrimination and calibration performance. Receiver operating characteristics (ROC) were derived at different time points. The discrimination performances are consistent across time. The area under the ROC curve at 5 years post treatment was 0.85 [95% CI: 0.81-0.88]. A goodness-of-fit test gives χ2(10)=5.3,p=0.9 demonstrating no evidence against the null hypothesis of zero difference between observed and expected onset of metastatic events. Results showed that at 80% sensitivity, 87% of UM patients will avoid unnecessary radiological scans. This provides potential cost savings of between £46,000 and £97,000 per year to the National Health Service assuming 600 new cases per year.

1 July 2008 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
ATAzzam F.G. Taktak
Azzam F.G. Taktak
AEAntonio Eleuteri
Antonio Eleuteri
SLStephen P. Lake
Stephen P. Lake
AFAnthony C. Fisher
Anthony C. Fisher